Journal article · 2026

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy

Cyrille Touzeau, Roberto Mina, Hang Quach, Vânia Hungria, Divaya Bhutani, Wenming Chen, S Satheesh Kumar, Chakra P. Chaulagain, Meletios Athanasios Dimopoulos, Nizar Jacques Bahlis, Senem Maral, Niels W.C.J. van de Donk and 36 more

New England Journal of Medicine, 395(5), 440–453 · Published 29 May 2026 · DOI 10.1056/nejmoa2603870

View at the publisherCite this paper

In brief

“Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy” is a 2026 journal article by Cyrille Touzeau and 47 co-authors, published in New England Journal of Medicine. OpenAlex counts 41 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
41
Most cited in
2026 (40)
Field-weighted impact
121.54
References
29
Authors
48

Abstract

BACKGROUND: The efficacy of teclistamab, a bispecific antibody targeting B-cell maturation antigen and CD3, as early-line monotherapy in relapsed or refractory multiple myeloma is unclear. METHODS: We randomly assigned patients with relapsed or refractory multiple myeloma who had previously received one, two, or three lines of therapy, including an anti-CD38 monoclonal antibody and lenalidomide, to… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Touzeau, C., Mina, R., Quach, H., Hungria, V., Bhutani, D., Chen, W., Kumar, S. S., Chaulagain, C. P., Dimopoulos, M. A., Bahlis, N. J., Maral, S., van de Donk, N. W., Filho, J. S., Saja, K., Teipel, R., Ando, M., Roeloffzen, W., Annibali, O., Augustson, B. M., . . . Landgren, O. (2026). Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. New England Journal of Medicine, 395(5), 440–453. https://doi.org/10.1056/nejmoa2603870

MLA 9

Touzeau, Cyrille, et al. “Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.” New England Journal of Medicine, vol. 395, no. 5, 2026, pp. 440–453. https://doi.org/10.1056/nejmoa2603870.

Chicago

Touzeau, Cyrille, Roberto Mina, Hang Quach, Vânia Hungria, Divaya Bhutani, Wenming Chen, S Satheesh Kumar, et al. 2026. “Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.” New England Journal of Medicine 395 (5): 440–453. https://doi.org/10.1056/nejmoa2603870.

Harvard

Touzeau, C. et al. (2026) ‘Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy’, New England Journal of Medicine, 395(5), pp. 440–453. doi:10.1056/nejmoa2603870.

IEEE

C. Touzeau et al., “Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy,” New England Journal of Medicine, vol. 395, no. 5, pp. 440–453, 2026, doi: 10.1056/nejmoa2603870.

BibTeX

@article{touzeau2026teclistamab,
  title     = {{Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy}},
  author    = {Touzeau, Cyrille and Mina, Roberto and Quach, Hang and Hungria, Vânia and Bhutani, Divaya and Chen, Wenming and Kumar, S Satheesh and Chaulagain, Chakra P. and Dimopoulos, Meletios Athanasios and Bahlis, Nizar Jacques and Maral, Senem and van de Donk, Niels W.C.J. and Filho, Jayr Schmidt and Saja, Khalid and Teipel, Raphael and Ando, Miki and Roeloffzen, Wilfried and Annibali, Ombretta and Augustson, Bradley M. and Botta, Cirino and Delforge, Michel and Bourgeois, Emmanuelle and Buda, Gabriele and Hus, Marek and Perrot, Aurore and Preis, Meir and Beksac, Meral and Pour, Luděk and Farmer, Sarah Leeth Hansen and Nunes, Marta and others},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  volume    = {395},
  number    = {5},
  pages     = {440--453},
  doi       = {10.1056/nejmoa2603870},
  url       = {https://doi.org/10.1056/nejmoa2603870}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments

  • teclistamab
  • relapsed/refractory multiple myeloma
  • bispecific antibodies
  • progression-free survival
  • overall survival
  • cytokine release syndrome
  • immune effector cell-associated neurotoxicity syndrome
  • lenalidomide

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Touzeau, C., Mina, R., Quach, H., Hungria, V., Bhutani, D., Chen, W., Kumar, S. S., Chaulagain, C. P., Dimopoulos, M. A., Bahlis, N. J., Maral, S., van de Donk, N. W., Filho, J. S., Saja, K., Teipel, R., Ando, M., Roeloffzen, W., Annibali, O., Augustson, B. M., . . . Landgren, O. (2026). Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. New England Journal of Medicine, 395(5), 440–453. https://doi.org/10.1056/nejmoa2603870

How many times has this paper been cited?

41 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Cyrille Touzeau, Roberto Mina, Hang Quach, Vânia Hungria, Divaya Bhutani, Wenming Chen, S Satheesh Kumar, Chakra P. Chaulagain, Meletios Athanasios Dimopoulos, Nizar Jacques Bahlis, Senem Maral, Niels W.C.J. van de Donk and 36 more.

What is the DOI of this paper?

10.1056/nejmoa2603870, permanently at https://doi.org/10.1056/nejmoa2603870. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.